For example, combination immunotherapy in which the vaccine is administered with the anti-CTLA-4 mAb has been demonstrated to significantly enhance anti-tumor immune responses compared to administration of either the vaccine or mAb alone (14). The gene discussed is CTLA4; the disease is neoplasm.